HOXB9 and melanoma: Further, in the Gide2019 melanoma cohort [35], the response rate to anti-CTLA- 4/anti-PD-1 therapy was 25% in high-HOXB9 expression patients, significantly lower than 71.4% in low-HOXB9 expression patients (Figure 8E).